Drug class profile · refreshed daily from federal data

PCSK9 Inhibitor

2 molecules in this class, $3.75B combined CY2024 Part D spend across 4.3M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the PCSK9 Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $3.75Bcombined across class
Total Rx claims: 4.3M1.1M unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Evolocumab

Brand: REPATHA · 3.7M Part D claims (CY24) · 931K beneficiaries · First FDA approval: 2018-10-09

Brand-only (no generics) 509 plans require PA

Low NADAC$281.70

→

Avg plan cost$281.86

Part D spend $3.25B 1× spread, current vs floor

Class share

87%

of class CY24 spend

View profile →

Alirocumab

Brand: Praluent · 647K Part D claims (CY24) · 161K beneficiaries · First FDA approval: 2015-07-24

Brand-only (no generics) 86 plans require PA

Low NADAC$257.84

→

Avg plan cost$257.91

Part D spend $494.4M 1× spread, current vs floor

Class share

13%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.